Nuvaxovid is the only protein-based, non-mRNA COVID-19 vaccine available in the United States for the 2025-2026 vaccination ...

In response to a call from President Donald Trump to make the positive impact of Covid-19 vaccines public, drug giant Pfizer ...

The U.S. Food and Drug Administration approved 2025-26 COVID-19 vaccines for anyone age 65 and older and any person 6 months ...

The U.S. Food and Drug Administration revoked the "Emergency Use Authorization" for COVID-19 vaccines. Here's what that means ...

The Food and Drug Administration has approved the 2025-2026 formulation of Nuvaxovid (COVID-19 Vaccine, Adjuvanted).

Novavax’s COVID-19 vaccine is not approved by the FDA yet, but it is available in the U.S. under emergency use authorization, which the FDA issued to the company in July 2022, and allows ...

Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a ...

Novavax (NASDAQ:NVAX) has received regulatory approval in Japan for its COVID-19 vaccine, Nuvaxovid, which has resulted in a ...

A new state standing order allows Washingtonians 6 months and older to receive an updated COVID-19 shot without a ...

Americans have another COVID-19 vaccine to choose from, after the Food and Drug Administration authorized on July 13 the vaccine developed by Maryland biotechnology company Novavax.

The FDA approval of this year's COVID-19 shots came with caveats, not universal recommendations. Here's what you need to know ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™ 2025-2026 ...